Compare iShares MSCI India ETF (INDA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MSCI India ETF trades at $47.52 (market cap $5.71B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 60 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| INDA | SYRE | |
|---|---|---|
Market Cap | $5.71B | $7.52B |
Volume | 3,011,243 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $108.92 |
52-Week Low | $45.42 | $22.18 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $47.24, up 1.99% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and pharmaceutical sector export issues. Recent news highlights India's energy security concerns and IT sector weakness, creating a cautious market environment despite the country's economic growth narrative.
The outlook remains cautious with technical weakness outweighing short-term gains. Investment opportunity exists for long-term exposure to India's growth story, but risks include energy sector instability, weather-dependent agricultural output, and global trade tensions affecting key export industries.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
